Type:14 Tablets
Generic Name:Telmisartan + Amlodipine
Manufacturer:Opsonin Pharma Limited
Price:৳308.00
Hypertension Initial Therapy: Patient may be initiated on Telmisartan/Amlodipine tablets if it is unlikely that control of blood pressure would be achieved with a single agent. The usual starting dose is 40/5 mg once daily. Patients requiring larger blood pressure reductions may be started with 80/5 mg once daily. OR Substitute for individually titrated components May increase dose after at least 2 weeks, not to exceed 80 mg/10 mg qDay Dosage range: Telmisartan 20-80 mg/amlodipine 2.5-10 mg PO qDay Initial therapy with Telmisartan/Amlodipine is not recommended in patients ?75 years old or with hepatic impairment. Hepatic Impairment Severe impairment: Titrate slowly; dose adjustment not recommended May be administered concomitantly with other anti-hypertensive agents
Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
May increase frequency and/or severity of angina during treatment initiation or dosage increments. Heart failure or hepatic impairment. Avoid fetal or neonatal exposure Hypotension: Correct any volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension. Titrate slowly in patients with hepatic or severe renal impairment Heart failure: Monitor for worsening Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker Myocardial infarction: Uncommonly, initiating a CCB in patients with severe obstructive coronary artery disease may precipitate myocardial infarction or increased angina Lactation: Discontinue drug or do not breast feed
Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters)
Telmisartan, a non-peptide angiotensin receptor blocker (ARB), is specific angiotensin II antagonist acting on the AT1 subtype. Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium, which leads to an increase in blood pressure (hypertension). Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Therefore, Telmisartan dilates blood vessels and reduces blood pressure without affecting pulse rate. Telmisartan has much greater affinity (>3,000 fold) for the AT1 receptor than for the AT2 receptor. It does not bind or block other hormone receptors or ion channels known to be important in cardiovascular regulation. Amlodipine, a dihydropyridine calcium-channel blocker (CCB), inhibits the transmembrane influx of calcium ion into vascular smooth muscle and cardiac muscle. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.
May be taken with or without food.
Treatment of hypertension, alone or with other anti-hypertensive agents. It may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Mild to moderate impairment: Dose adjustment not recommended
>10% Peripheral edema (1-11%) 1-10% Dizziness (3%),Orthostatic hypotension (6%),Syncope (2%),Back pain (2%)
Known hypersensitivity to this product or any of its components. Pregnancy & lactation. Biliary obstructive disorders, severe hepatic impairment, hypotension, cardiogenic shock, left ventricle outflow tract obstruction.
